NCT05644314Recruiting
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study
Source: ClinicalTrials.gov · Last updated 14 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 16 Nov 2022
- Start date
- 1 May 2022
- Primary completion date
- 31 May 2026
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Stroke
- NCT number
- NCT05644314
What you commit to
- Study type: Interventional
- Planned participants: 144
- From 1 May 2022 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;
- Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;
Other illness
- Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;
- Gastrointestinal disease with active bleeding;
Other
- Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;
- Life expectancy less than 12 months;
- the investigator judged patients to be unsuitable for participation in this study.
Who the study is looking for
- Age ≥ 18 years old, gender is not limited;
- Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;
- Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hospital of Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.